ArticleCancers2010
Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.
Article in Cancers, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Evaluation of soluble mesothelin-related peptides and MSLN genetic variability in asbestos-related diseases.Radiology and oncology · 2020Article
- NLRP3 and CARD8 polymorphisms influence risk for asbestos-related diseases.Journal of medical biochemistry · 2020Article
- Epigenetic Regulation of miRNA Expression in Malignant Mesothelioma: miRNAs as Biomarkers of Early Diagnosis and Therapy.Frontiers in oncology · 2019Review
- Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.International journal of medical sciences · 2018Article
- CD44 and its ligand hyaluronan as potential biomarkers in malignant pleural mesothelioma: evidence and perspectives.Respiratory research · 2017Review
- Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo.Scientific reports · 2016Article
- Reactive oxygen species a double-edged sword for mesothelioma.Oncotarget · 2015Review
- Chemokine (C-C motif) ligand 3 detection in the serum of persons exposed to asbestos: A patient-based study.Cancer science · 2015Article
- Unusual presentation and location pleural malignant mesothelioma.BMJ case reports · 2013Article
- Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.Cancer genetics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malignant mesothelioma (MM) is a rare and aggressive tumour of the serosal cavities linked to asbestos exposure. Improved detection methods for diagnosing this type of neoplastic disease are essential for an early and reliable diagnosis and treatment. Thus, focus has been placed on finding tumour markers for the non-invasive detection of MM. Recently, some blood biomarkers have been described as potential indicators of early and advanced MM cancers. The identification of tumour biomarkers alone or in combination could greatly facilitate the surveillance procedure for cohorts of subjects exposed to asbestos, a common phenomenon in several areas of western countries.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.